ENLV, IL0011319527

Enlivex stock trades at 1.14 euros on Lang & Schwarz

Published on 11/08/2026 at 13:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enlivex stock is advancing Allocetra for osteoarthritis. It also manages a treasury strategy focused on Rain prediction markets.

Business Focus And Clinical Milestones

Enlivex develops Allocetra for osteoarthritis and manages a treasury strategy focused on Rain prediction markets.
The company reported favorable 12-month topline data from an Allocetra Phase I/IIa trial and is advancing a Phase 2b program.

ENLV, IL0011319527, Illustration mit AI erstellt.

Enlivex stock traded at 1.14 euros on Lang & Schwarz at 13:04 CET on Saturday, November 7, 2026. The quote was unchanged from the previous 1.14 euros.

Enlivex develops Allocetra, a therapy candidate for osteoarthritis, while pursuing a treasury strategy focused on the Rain prediction markets protocol. The company describes these as parallel engines for shareholder value on its investor page.

Clinical Program Remains In Focus

Enlivex said its 12-month topline data from a Phase I/IIa Allocetra trial showed a clinically meaningful response in 79.2 percent of patients aged 64 and older, compared with 47.6 percent in the placebo group. The company reported a p-value of 0.027 for that comparison.

The investor page also lists an ongoing Phase 2b trial in age-related primary moderate-to-severe knee osteoarthritis. Topline six-month data are expected by mid-2027, according to the company.

Investors can follow the real-time quote of Enlivex stock.

The broader US equity market is covered on the S&P 500 topic page.

More news and analyses on Enlivex stock are available in the company topic.